Navigation Links
Opexa Therapeutics Reports Positive Top-line Data in Phase I/II,Dose Escalation Trial with Tovaxin for Multiple Sclerosis

ion of CD8+ cytotoxic T-cells and CD4+CD25+FoxP3 Tregs specific for T-cell vaccine. The induction of anti-idiotypic cytotoxic CD8+ effector T-cells and anti-ergotypic CD4+CD25+FoxP3 positive Tregs is believed to provide a therapeutically effective dual mechanism of protection to patients treated with Tovaxin(TM). The observed regulatory immune responses have been shown to collectively correlate with clinical improvement in treated patients.

About Opexa Therapeutics

Opexa Therapeutics develops and commercializes cell therapies to treat autoimmune diseases such as MS, rheumatoid arthritis, and diabetes. The Company is focused on autologous cellular therapy applications of its proprietary T-cell and stem cell therapies. The Company's lead product, Tovaxin(TM), a T-cell therapy for multiple sclerosis is in Phase IIb trials. The Company holds the exclusive worldwide license for adult multipotent stem cells derived from mononuclear cells of peripheral blood. The technology allows large quantities of monocyte derived stem cells to be produced efficiently for use in autologous therapy, thus circumventing the threat of rejection. The Company is in preclinical development for diabetes mellitus. For more information, visit the Opexa Therapeutics website at www.opexatherapeutics.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements about Opexa Therapeutics' growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. These forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Opexa Therapeutics' ability to obtain additional funding, develop its stem cell technologies, achieve its operational objectives, and obtain patent protection
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Opexa Advances Monocyte Derived Islet Technology to Proof of Principle in stz-induced NOD/SCID Mice
2. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
3. Opexa Presents Tovaxin Research at Federation of Clinical Immunology Societies Annual Meeting
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
6. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
7. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
8. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
9. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
(Date:9/18/2014)... KANSAS CITY, Kan. , Sept. 18, 2014 ... ), a pet therapeutics company focused on licensing, ... animals, today announced the full exercise of the ... common stock in connection with the company,s previously ... stock.  All of the shares are being offered ...
(Date:9/18/2014)... 2014  LABSCO, the leading specialty sales ... to hospitals, physician office laboratories and alternate ... agreement with Sysmex America.  This agreement is ... the Sysmex XS-1000 i ™, Sysmex pocH-100 ... Automated Hematology Analyzers. The agreement ...
(Date:9/18/2014)...   MacPractice,s MacPractice MD MU version 5.0 ... which designates that the software is capable of supporting ... 2 Meaningful Use measures required to qualify for funding ... MD MU version 5.0 was certified on June 6, ... the National Coordinator-Authorized Certification Body (ONC-ACB) and is compliant ...
Breaking Medicine Technology:Aratana Therapeutics, Inc. Announces Full Exercise of Underwriters' Option to Purchase Additional Shares 2LABSCO Renews Sysmex Distributorship Agreement 2LABSCO Renews Sysmex Distributorship Agreement 3MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 2MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 3MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 4MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 5
... Nov. 16, 2010 eMix , a new business venture ... of its cloud-based image sharing technology for studies and ... expansion into the European marketplace, starting in Germany, Austria and Switzerland. ... features are: Automated report delivery – Enables a ...
... 2010 Berger & Montague, P.C. and ... for Lead Plaintiff and the Class in ... announced the following:IN THE UNITED STATES DISTRICT ... HEMISPHERX:BIOPHARMA, INC. LITIGATION:CIVIL ACTION NO.  09-CV-5262-PSD:SUMMARY NOTICE ...
Cached Medicine Technology:At RSNA, eMix to Exhibit EMR Delivery, Other New Features 2Summary Notice of Proposed Settlement, Settlement Fairness Hearing, and Motion for Award of Attorneys' Fees and Reimbursement of Litigation Expenses 2Summary Notice of Proposed Settlement, Settlement Fairness Hearing, and Motion for Award of Attorneys' Fees and Reimbursement of Litigation Expenses 3
(Date:9/18/2014)... When Mary Ann Thompson and Mathieu Nikel decided it ... Bali, Indonesia with their son, Isaac, said there was only one ... Mercy College in 2001 when Thompson was an undergraduate student and ... student at the time, was French and so she asked him. ... the United States when she was 7 years old. Nikel ...
(Date:9/18/2014)... 2014 Dr. David A. F. Ellis ... American Academy of Facial Plastic and Reconstructive Surgery and ... Division of Facial Plastic Surgery. He is recognized ... surgery. , Dr. Ellis will be presenting on ... presenting on injection techniques and various treatments for complications ...
(Date:9/18/2014)... News) -- Rising temperatures in the Atlantic Ocean may ... waters that are becoming warmer, an expansion that could ... A study of 40 species along the reefs ... the invasive and poisonous lionfish, according to researchers from ... University of North Carolina-Wilmington, who published their findings in ...
(Date:9/18/2014)... September 18, 2014 It’s been just a ... newest, patent pending bunion splint to website visitors, but already ... wrote: "I was absolutely delighted. It is perfect and I ... am wearing them. THANK YOU FOR LISTENING!!!" Another user ... saying, "The hole used to slip to the end of ...
(Date:9/18/2014)... Amy Norton HealthDay Reporter ... single dose of a common antidepressant can quickly alter the ... The findings, reported online Sept. 18 in ... brain,s response to widely prescribed antidepressants. Experts said the hope ... depression are likely to benefit from a drug -- and ...
Breaking Medicine News(10 mins):Health News:For The First Time in Over a Decade Mercy College Alumni Marry at College 2Health News:Dr. David A. F. Ellis Has Been Invited to Speak at a Conference of the American Academy of Facial Plastic and Reconstructive Surgery in Orlando, Florida 2Health News:Rising Atlantic Ocean Temperatures Could Pose Threat to Reefs 2Health News:Feedback for the New Bunion Bootie Design Feedback is Already Pouring In, and Bunion Sufferers Love It 2Health News:Feedback for the New Bunion Bootie Design Feedback is Already Pouring In, and Bunion Sufferers Love It 3Health News:One Dose of Antidepressant Changes Brain Connections, Study Says 2Health News:One Dose of Antidepressant Changes Brain Connections, Study Says 3
... in sub-Saharan Africa do not necessarily lead to a higher ... Friday. ,Contradicting a "common belief" of such ... for Refugees (UNHCR) said that out of 12 refugee camps ... rate than surrounding host communities. ,The study, led ...
... 105-year-old exile who was detained for 30 years in his native ... citizen at a ceremony in Miami. ,Now, he ... ,And the former fisherman is convinced he will outlive the ... ,"He's far less healthy than I am, he can hardly ...
... lovers, otherwise allergic, beware. Cuddling your pet could prove ... found that a protein secreted from the cats skin could ... in people who have no specific allergy to the animals. ... suffer from allergy of one kind or another. ...
... of The American Journal of Medicine, researchers from the ... people 45 to 64 years of age who added ... cardiovascular disease (CVD) and reduce their death rate. ... at least 5 fruits and vegetables daily, exercising at ...
... - a molecule originally considered only a lowly messenger for ... where they are in the body and what they ... Medicine have discovered. ,The finding implies that ancient ... the human genome - a cell's genetic blueprint. It also ...
... autoimmune disease that mainly affects women in their reproductive ... improving quality of life. ,For men with ... However, no studies have been conducted to date on ... male SLE patients. In addition, the study identified intravenous ...
Cached Medicine News:Health News:No Clear Link Between Conflict, Rape and HIV: UN Study 2Health News:The American Dream Comes True for 105-year-old Cuban 2Health News:Allergic Individuals Should Keep Away from Cats, Say UK Scientists 2Health News:Allergic Individuals Should Keep Away from Cats, Say UK Scientists 3Health News:Healthy Lifestyle can Reduce Cardiovascular Risk 2Health News:RNA Play a Vital Role in Gene Activity 2Health News:RNA Play a Vital Role in Gene Activity 3Health News:RNA Play a Vital Role in Gene Activity 4Health News:Infertility is Seen in Men With SLE 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: